Search results
Showing 151 to 200 of 1380 results for patients and public
Organisations that can use the NICE electronic and print content framework
Tobacco: preventing uptake, promoting quitting and treating dependence (NG209)
This guideline covers support to stop smoking for everyone aged 12 and over, and help to reduce people's harm from smoking if they are not ready to stop in one go . It also covers ways to prevent children, young people and young adults aged 24 and under from taking up smoking. The guideline brings together and updates all NICE's previous guidelines on using tobacco, including smokeless tobacco . It covers nicotine replacement therapy and e-cigarettes to help people stop smoking or reduce their harm from smoking. It does not cover using tobacco products such as ‘heat not burn’ tobacco.
Show all sections
Sections for NG209
- Overview
- Recommendations on preventing uptake
- Recommendations on promoting quitting
- Recommendations on treating tobacco dependence
- Recommendations on treating tobacco dependence in pregnant women
- Recommendations on policy, commissioning and training
- Terms used in this guideline
- Recommendations for research
This guideline covers support for disabled children and young people with severe complex needs, from birth to 25 years. It aims to encourage education, health and social care services to work together and provide more coordinated support to children and young people, and their families and carers.
Show all sections
Sections for NG213
- Overview
- Recommendations on support for all disabled children and young people with severe complex needs
- Recommendations on specialist support for disabled children and young people with particular needs
- Recommendations on service organisation, integration and commissioning
- Terms used in this guideline
- Recommendations for research
- Rationale and impact for recommendations on supporting all disabled children and young people with severe complex needs
- Rationale and impact for recommendations on specialist support for disabled children and young people with particular needs
This indicator covers the rate of people admitted with a primary diagnosis of hip fracture per 100,000 population. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG24
This quality standard covers diagnosing and managing hip fracture in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS16Show all sections
Sections for QS16
- Quality statements
- Quality statement 1: Multidisciplinary management
- Quality statement 2: Timing and expertise for surgery
- Quality statement 3: Intracapsular fracture
- Quality statement 4: Trochanteric fracture
- Quality statement 5: Subtrochanteric fracture
- Quality statement 6: Rehabilitation after surgery
- Update information
This guideline covers managing hip fracture in adults. It aims to improve care from the time people aged 18 and over are admitted to hospital through to when they return to the community. Recommendations emphasise the importance of early surgery and coordinating care through a multidisciplinary Hip Fracture Programme to help people recover faster and regain their mobility.
Tributes paid following the death of founding NICE chairman Professor Sir Mike Rawlins
As founding chairman of NICE, Sir Mike led NICE from 1999 to 2013, through its early formative years to its current position as a world leader in health and social care guidance and medicine evaluation.
Early value assessment is a new evidence-based approach designed to improve the care of people and effective use of NHS resources through quicker access to promising health technologies that address national unmet need. It champions stronger partnership working between regulatory, healthcare and research organisations to benefit people and better support innovators while ensuring value for money for the NHS
This quality standard covers support and treatment to stop smoking and stop using smokeless tobacco, and harm-reduction approaches for people who are not ready to stop in one go. It describes high-quality care in priority areas for improvement.
View quality statements for QS207Show all sections
Sections for QS207
- Quality statements
- Quality statement 1: Identifying people who use tobacco
- Quality statement 2: Advice
- Quality statement 3: Tobacco cessation support and treatment
- Quality statement 4: Harm-reduction approach
- Quality statement 5: Treatment to stop smoking in hospital
- Update information
- About this quality standard
Esketamine nasal spray for treatment-resistant depression (TA854)
Evidence-based recommendations on esketamine (Spravato) for treatment-resistant depression in adults.
or care needs. Our guidance goes beyond NHS care to cover social care and public health. Find out more about how to access treatment and...
learning disability and their families are left vulnerable to crisis and in-patient admissions, as well as being left reliant on harmful...
Celebrating the people who support NICE: International Volunteer Day
Applauding the members of the public who donate their valuable experience and insight to NICE
A review of the impact our evidence-based guidance has on improvements in lung cancer.
Find out more about the progress made in implementing NICE guidance on cardiovascular disease prevention
Find out about the progress made by the health and care system in implementing NICE guidance on end of life care for adults
Find out about the progress made by the health and care system in implementing NICE guidance on prostate cancer
Find out about the progress made by the health and care system in implementing NICE guidance on respiratory conditions
Find out about the progress made by the health and care system in implementing NICE guidance on children and young people's healthcare
Find out about the progress made by the health and care system in implementing NICE guidance on cardiovascular disease management
Tunnelled peritoneal drainage catheter insertion for refractory ascites in cirrhosis (IPG746)
Evidence-based recommendations on tunnelled peritoneal drainage catheter insertion for refractory ascites in cirrhosis. This involves inserting a catheter under the skin in the abdomen to drain excess fluid when needed, at home or in community care. The aim is to reduce the need for hospital admissions and improve quality of life.
View recommendations for IPG746Show all sections
Evidence-based recommendations on ab interno canaloplasty for open-angle glaucoma. This involves widening the channel that drains fluid from the eye. The aim is to reduce pressure in the eye.
View recommendations for IPG745Show all sections
Advocacy services for adults with health and social care needs (NG227)
This guideline covers advocacy for people using health and social care services in all adult settings (including young people under 18 using adult services). It describes how to commission and deliver effective advocacy, as well as identifying who should be offered advocacy (including who is legally entitled to it). It also covers monitoring and improving advocacy services, and training and skills for advocates and practitioners.
to support shared decision making, including NICE's information for the public. Ensure that people and their families and carers...
Towards a new partnership – NICE and the voluntary and community sector
Victoria Thomas gives details of NICE’s new voluntary and community sector forum, which brings together a range of organisations, including health and care sector charities and not for profit groups, and gives them an opportunity to share their views and help shape NICE’s work in the future
reported internationally, despite surgery being carried out on older, less fit patients. That has been achieved by a doubling of the...
How people can have an impact on NICE guidance
The section of the NICEimpact lung cancer report looking at how lung cancer can be prevented.
The section of the NICE impact lung cancer report looking at how lung cancer is detected.
Evidence-based recommendations on transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine in adults. This involves attaching a small device on the forehead to send small electrical currents to the nerves that bring sensation to the upper eyelids, forehead and scalp.
View recommendations for IPG740Show all sections
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)
Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected stage 2B and 2C melanoma in people 12 years and over.
Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy.
Evidence-based recommendations on relugolix–estradiol–norethisterone acetate (Ryeqo) for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.
An outline of the key principles that are universal to all of NICE's guidance and standards.
NICE and the MHRA have been awarded £1.8m funding by Wellcome over three years to explore and produce guidance on regulating digital mental health tools.
Using our guidelines to help people make decisions about their care
to support shared decision making , including NICE's information for the public .• Ensure that people (and their families and carers as...
to support shared decision making , including NICE's information for the public. • Ensure that people (and their families and carers as...
Dr Sam Roberts welcomes Dr Michael Borowitz as new NICE non-executive director
New NICE non-executive director appointment approved by the Secretary of State for Health and Social Care
Neurostimulation of lumbar muscles for refractory non-specific chronic low back pain (IPG739)
Evidence-based recommendations on neurostimulation of lumbar muscles for refractory non-specific chronic low back pain in adults. This involves implanting a pulse generator under the skin of the upper buttock or lower back, which the person can use to manage their pain.
View recommendations for IPG739Show all sections
Evidence-based recommendations on prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia. This involves positioning a temporary implant in the urethra to increase the flow of urine.
View recommendations for IPG737Show all sections
Weight management: BMI calculation in preceding 5 years (IND167)
This indicator covers the percentage of patients aged 18 or over who have had a record of a BMI being calculated in the preceding 5 years (and after their 18th birthday). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM143
Contrast-enhanced spectral mammography for breast cancer (MIB304)
NICE has developed a medtech innovation briefing (MIB) on contrast-enhanced spectral mammography for breast cancer .
Focal resurfacing implants to treat articular cartilage damage in the knee (IPG734)
Evidence-based recommendations on focal resurfacing implants to treat articular cartilage damage in the knee in adults. This involves replacing the damaged area with an artificial implant.
View recommendations for IPG734Show all sections
Transcutaneous electrical neuromuscular stimulation for urinary incontinence (IPG735)
Evidence-based recommendations on transcutaneous electrical neuromuscular stimulation for urinary incontinence in adults. This involves stimulating nerves and muscles in the pelvic floor to strengthen the muscles and reduce urine leaks.
View recommendations for IPG735Show all sections
Superficial venous arterialisation for chronic limb threatening ischaemia (IPG736)
Evidence-based recommendations on superficial venous arterialisation for chronic limb threatening ischaemia in adults. This involves joining an artery in the lower leg to a large vein to divert blood flow through the vein towards the foot, bypassing the blocked arteries.
View recommendations for IPG736Show all sections
This indicator covers the percentage of adults receiving drug treatment for epilepsy who had a structured review in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM209
Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (HTE2)
Evidence-based recommendations on cefiderocol for treating severe drug-resistant gram-negative bacterial infections....
Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections....
View recommendations for HTE1Show all sections
Evidence standards framework for digital health technologies (ECD7)
This document describes an evidence standards framework (ESF) for digital health technologies (DHTs). It was developed by NICE between June 2018 and February 2019 in collaboration with NHS England, Public Health England and MedCity. The work was commissioned by NHS England.
Show all sections
- Overview
- Introduction
- Section A: Technologies suitable for evaluation using the evidence standards framework
- Section B: Classification of digital health technologies
- Section C: Evidence standards tables
- Terms used in the evidence standards framework
- How to meet the standards
- Section D: Early deployment standards for evidence-generation programmes